Lisata Therapeutics, Inc.는 임상 단계 제약 회사로, 고형암 및 기타 질병 치료를 위한 치료제 발견, 개발 및 상업화를 영위하고 있습니다. 이 회사의 주요 임상 개발 제품인 certepetide는 전이성 췌관 선암, 담도암, 충수암, 결장암 및 교모세포종 등 다양한 고형암 치료를 위해 여러 항암 요법과 병용하여 2상 임상 연구가 진행 중입니다. 이 회사는 1980년에 설립되었으며, 본사는 뉴저지주 배스킹리지에 있습니다.
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with range of anti-cancer regimens. Lisata Therapeutics, Inc. was formerly known as Caladrius Biosciences, Inc. and changed its name to Lisata Therapeutics, Inc. in September 2022. The company was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
